Table 1 Clinical and epidemiological information from patients included in the study

From: Coinfection with chikungunya and Zika results in mild disease and distinct inflammatory response

Variables

Coinfected

CHIKV

ZIKV

p

n = 12

n = 13

n = 13

 

Agea

 

39 [28–60]

34 [21–46]

43 [37–57]

0.093

Sex (%)b

 Female

9 (75)

9 (71.2)

11 (78.6)

0.6479 c

Cycle threshold in RT-qPCR

 CHIKV+ Ct

28.4 [20.2–37.4]

20.4 [18.5–21.7]

-

<0.0001d

 ZIKV+ Ct

37.5 [36.7–37.7]

-

37.2 [36.7–37.7]

Symptoms

 Fever

11 (91.7)

13 (100)

8* (61.5)

0.018

 Arthralgia

11 (91.7)

13 (100)

12 (92.3)

0.576

 Exanthema

9 (75)

4 (30.8)

7 (53.8)

0.086

 Conjunctivitis

2 (16.7)

6 (46.1)

2 (15.4)

0.134

 Myalgia

8 (66.7)

10 (76.9)

12 (92.3)

0.284

 Retro-orbital pain

4 (33.3)

9 (69.2)

6 (46.1)

0.188

Lymphadenopathy

5 (41.7)

2 (15.4)

1 (7.7)

0.094

Medication used

 H1 receptor antagonists

1 (8.3)

0

4 (30.8)

0.057

 NSAIDs

8 (66.7)

4 (30.8)

9 (69.2)

0.090

 Analgesic

10 (83.3)

8 (61.5)

10 (76.9)

0.441

 Antipyretic

7 (58.3)

6 (46.1)

8 (61.5)

0.708

Chronic co-morbidities

 Rhinitis

1 (8.3)

0

3 (23.1)

0.152

 Asthma

0

0

2 (15.4)

0.131

 Arterial hypertension

1 (8.3)

1 (7.7)

0

0.576

 Diabetes

0

1 (7.7)

0

0.372

  1. adata shown as median plus interquartile range (25%-75%).
  2. bdata shown as n plus percentage for group.
  3. cData tested with: Fisher’s exact test (for association comparisons); Mann-Whitney test (for continuous variables).
  4. dKruskal-wallis test followed by Dunn test (significant difference between CHIKV x ZIKV (p = 0.006)).
  5. *The Chi-square posttest show the difference in ZIKV compared to CHIKV + ZIKV and CHIKV
  6. Bold indicates statistical significative differences (p < 0.05).
Back to article page